This guidance clarifies the requirements for product name placement, size, prominence, and frequency in promotional labeling and advertisements for prescription drugs. The disclosure of the product name in promotional labeling and advertisements is important for proper identification and to ensure safe and effective use. This guidance also articulates the circumstances under which FDA intends to refrain from taking enforcement action regarding these requirements. We believe that following this guidance will allow for appropriate advertising and promotion without presenting any public health risk to patients.
News & Trends
Procurar
Recentes
- Plano de Controlo de Qualidade e Conformidade Legal de SUPLEMENTOS ALIMENTARES: ” Formação muito útil para o desempenho das minhas funções “
- MHRA Registration of medical devices
- The Use of Data in Public Health. Understanding the Potential for Artificial Intelligence in Medicine
- UK Government confirms indefinite recognition of CE marked medical devices
- Methodological Principles for the Assessment of Section 5.1 of the Summary of Product Characteristics
- Good manufacturing practice (GMP) Multistakeholder workshop on expert contributions to artificial intelligence guidance development (Annex 22)
- PIC/S PE 009-18 – Guide to GMP for Medicinal Products | Part I
- EMA Updates Information Page on Bioequivalence Guidelines

